Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTLC) reported FY2025 net income of $249.0M driven mainly by a $365.4M non-cash increase in the fair value of its GMP Bio joint-venture investment and a $111.6M deferred tax provision. The company reported $0.59 basic EPS, no product revenue, formalized JV subsidiaries Sapu Bio and Sapu Nano, advanced six Deciparticle™ candidates and completed a Phase 1 OT-101/IL-2 combination trial. The JV’s GMP manufacturing facility remained fully operational and the PDAOAI knowledge platform expanded substantially during 2025.
Oncotelic Therapeutics (OTCQB: OTLC) announced placement in an editorial published April 10, 2026 by AINewsWire, part of the Dynamic Brand Portfolio at InvestorBrandNetwork.
The piece links AI-driven manufacturing and continuous compliance to scalable efficiency and cost advantages, noting alignment with Oncotelic's biotech and advanced digital systems focus.
Oncotelic Therapeutics (OTLC) announced a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform on April 2, 2026.
The integrated system targets automated material handling, real-time monitoring, audit-ready documentation (IQ/OQ/PQ) and scalable manufacturing through a joint development, manufacturing, and licensing agreement.
Sapu Nano (parent Oncotelic Therapeutics, OTCQB:OTLC) will introduce its Deciparticle™ nanomedicine platform and present its clinical pipeline at BIO-Europe Spring 2026 on March 25, 2026.
The company will highlight platform-level advantages—sub-20 nm design, improved pharmacokinetics, better tissue targeting, and reduced excipient toxicities—and two lead intravenous candidates: Sapu003 (everolimus for injection) and Sapu006 (docetaxel for injection), both entering Phase 1 trials. Sapu Nano is seeking strategic partnerships and co-development opportunities to advance clinical development and commercialization.
Sapu Nano (OTLC) will present new everolimus toxicology data at the Society of Toxicology (SOT) 2026 Annual Meeting on March 23, 2026. The poster (Abstract #3539; Board K692) reports tissue concentration–driven effects and links tissue exposure to organ‑specific toxicity, informing delivery strategies.
Authors W. Chang, N. Chang, T. Hoque, and C. Lee will be available during the Poster Session: ADME/Toxicokinetics I, Author Attended 1:45 PM–4:15 PM, Display Time 9:00 AM–4:30 PM, Exhibit Hall B, San Diego Convention Center.
Oncotelic Therapeutics (OTCQB: OTLC) announced expanded international intellectual property coverage for OT-101, its TGF-β antisense drug-delivery platform, strengthening protection across neurology, oncology and CNS drug‑delivery technologies aimed at crossing the blood–brain barrier.
The company was also featured in a BioMedWire editorial on Feb 20, 2026 highlighting investor interest in clinical‑stage, cross‑indication assets.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial on Feb 18, 2026 highlighting investor and acquirer preference for de-risked, late-stage biotech assets.
The company said it recently achieved key global intellectual property advancements supporting OT-101, its TGF-β antisense therapeutic platform, and holds multiple clinical- and late-stage programs in oncology and CNS indications, aligning with current M&A priorities.
Oncotelic Therapeutics (NASDAQ:OTLC) and Sapu Bioscience expanded OT-101 intellectual property to strengthen a CNS and neurology commercialization pathway. Australia allowed Parkinson’s Disease claims for OT-101 (SEQ ID NO:9) covering treatment methods and CNS delivery routes. China and Germany granted utility model patents for continuous intracranial infusion devices (CN 222693486 U; DE 21 2023 000 368.6) with device-term protection noted through 2033. The company positions these filings as a layered patent wall to support partnering, development, and long-term commercial defensibility for oncology and neurology uses.
Oncotelic Therapeutics (OTLC) reported 2025 progress and set priorities for 2026, highlighting platform validation, clinical advancement, and asset valuation.
Key 2025 achievements include unveiling the PDAOAI knowledge platform, completing a Phase 1 OT-101 combination trial, initiating first-in-human testing of IV everolimus Deciparticle (Sapu-003), multiple peer-reviewed publications, a Medicilon partnership for IND-enabling work, and an independent valuation of the GMP Bio JV pipeline at approximately $1.7 billion.
Oncotelic (OTLC) opened access to PDAOAI, its evidence-interrogation platform, and published a curated TGF-β literature corpus to a dedicated Discord research channel on Dec 22, 2025. PDAOAI embeds, clusters, and queries large biomedical datasets to surface citation-backed, testable hypotheses rather than training bespoke LLMs on proprietary data. The corpus includes more than 125,000 PubMed abstracts. The platform has supported seven peer-reviewed publications and is positioned to aid biomarker prioritization, precision trial design, and translational decision-making.